Showing results (21-30 of 65) with videos related to

Sort By:
Pageof 7
Clinical Lymphoma, Myeloma & Leukemia|June 7, 2024
Detangling the Threads of Hairy Cell Leukemia, Beyond the Morphology and Into the MolecularDanielle Brazel, David Hermel, Pranav Gandhi, et al.
Expert Review of Hematology|November 25, 2010
Hairy cell leukemia: current therapies and future directionsGregory S Vosganian, Darren S Sigal, Alan Saven
American Journal of Clinical Oncology|October 29, 2014
Retrospective analysis of relative dose intensity in patients with non-Hodgkin lymphoma receiving CHOP-based chemotherapy and pegfilgrastimLodovico Balducci, May Mo, Esteban Abella, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 10, 2025
Evaluation of ambulatory use of daratumumab hyaluronidase injectionNoah Vannarat, David J Hermel, Anne M Spengler
Journal of Investigative Medicine High Impact Case Reports|May 28, 2016
Spontaneous Iliopsoas Muscle Hemorrhage Secondary to Ibrutinib (Imbruvica; Pharmacyclics): Brief ReportAnna Sarcon, Gregory P Botta, Nikunj Patel, et al.
Blood|January 9, 2010
Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribineDarren S Sigal, Robert Sharpe, Carol Burian, et al.
Blood|November 7, 2013
Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution seriesJoshua D Rosenberg, Carol Burian, Jill Waalen, et al.
Journal of Gastrointestinal Oncology|March 2, 2013
Masquerade without a mass: an unusual cause of severe acute pancreatitisChristina A To, Michael M Quigley, Alan Saven, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2003
Extended follow-up of patients with hairy cell leukemia after treatment with cladribineGrant R Goodman, Carol Burian, James A Koziol, et al.
Future Oncology (London, England)|November 4, 2021
The role of Globo H and SSEA-4 in the development and progression of cancer, and their potential as therapeutic targetsDarren S Sigal, David J Hermel, Pei Hsu, et al.
Pageof 7